Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy


Por: Kelleher, N, Garcia, O, Gallardo, D, Gonzalez-Campos, J, Hernandez-Rivas, JM, Montesinos, P, Sarra, J, Gil, C, Barba, P, Guardia, R, Brunet, S, Bernal, T, Martinez, MP, Abella, E, Bermudez, A, Sanchez-Delgado, M, Antonia, C, Gayoso, J, Calbacho, M, Ribera, JM

Publicada: 2 ene 2016
Resumen:
Acute lymphoblastic leukemia (ALL) following solid organ or hematologic malignancy (secondary ALL, s-ALL) is not well characterized. We analyzed the characteristics and outcome of patients with s-ALL and compared them with those of patients with de novo- ALL. Of 448 patients, 24 (5%) had previous neoplasia. Sixteen patients had received previous cytotoxic therapy (therapy-associated ALL, t-ALL), and eight had not (antecedent-malignancy ALL, am-ALL). Except for more advanced age in patients with s-ALL, no statistically significant differences were observed in WBC count, CNS involvement, immunophenotype or cytogenetics between the groups, nor in complete remission (t-ALL: 94%; am-ALL: 75%; de novo-ALL: 85%), 3-year remission duration (58%; 50%; 72%), overall survival (71%; 38%; 60%) or event-free survival (53%, 38%; 53%). Our study did not show poor clinical or cytogenetic features or inferior outcome in ALL patients with antecedent neoplastic disease, irrespective of the type of treatment received for the neoplasia.

Filiaciones:
Kelleher, N:
 Hosp Doctor Josep Trueta, Dept Hematol, Inst Catala Oncol, Girona, Spain

Garcia, O:
 Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Inst Catala Oncol, Hematol Dept,Jose Carreras Res Inst, Badalona, Spain

Gallardo, D:
 Hosp Doctor Josep Trueta, Dept Hematol, Inst Catala Oncol, Girona, Spain

Gonzalez-Campos, J:
 Hosp Univ Virgen del Rocio, Dept Hematol, Seville, Spain

Hernandez-Rivas, JM:
 Univ Salamanca, CSIC Salamanca, Ctr Invest Canc, Hematol Dept,Hosp Univ Salamanca,IBCC, E-37008 Salamanca, Spain

 Univ Salamanca, CSIC Salamanca, Ctr Invest Canc, Dept Hematol,IBSAL,IBCC, E-37008 Salamanca, Spain

Montesinos, P:
 Hosp Univ & Politecn La Fe, Dept Hematol, Valencia, Spain

Sarra, J:
 Hosp Duran & Reynals, Inst Catala Oncol, Lhospitalet De Llobregat, Spain

Gil, C:
 Hosp Gen Univ Alicante, Dept Hematol, Alicante, Spain

Barba, P:
 Hosp Valle De Hebron, Dept Hematol, Barcelona, Spain

Guardia, R:
 Hosp Doctor Josep Trueta, Dept Hematol, Inst Catala Oncol, Girona, Spain

Brunet, S:
 Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain

Bernal, T:
 Hosp Cent Asturias, Dept Hematol, Oviedo, Spain

Martinez, MP:
 Hosp Doce Octubre, Dept Hematol, Madrid, Spain

Abella, E:
 Hosp del Mar, Dept Hematol, Barcelona, Spain

Bermudez, A:
 Hosp Marques Valdecilla, Dept Hematol, Santander, Spain

Sanchez-Delgado, M:
 Hosp Gen Univ Valencia, Dept Hematol, Valencia, Spain

Antonia, C:
 Hosp Son Llatzer, Dept Hematol, Palma de Mallorca, Spain

Gayoso, J:
 Hosp Gen Univ Gregorio Maranon IiGSM, Dept Hematol, Madrid, Spain

Calbacho, M:
 Hosp Ramon & Cajal, Dept Hematol, E-28034 Madrid, Spain

Ribera, JM:
 Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Inst Catala Oncol, Hematol Dept,Jose Carreras Res Inst, Badalona, Spain
ISSN: 10428194





LEUKEMIA & LYMPHOMA
Editorial
TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 57 Número: 1
Páginas: 86-91
WOS Id: 000368025700018
ID de PubMed: 25860236

MÉTRICAS